REGN

La cadena de opciones muestra datos clave de las opciones de acciones de Regeneron Pharmaceuticals a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Regeneron Pharmaceuticals..

Regeneron Pharmaceuticals (NASDAQ:REGN) Bolsa, Cadena de Opciones

Regeneron Pharmaceuticals

Regeneron Pharmaceuticals Inc discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).

Eli Lilly and Co.

Equities

Government

News

Markets

ABBV

AMGN

FTXH

GILD

iShares Dow Jones US Pharmaceuticals Index Fund

KURE

PILL

Merrill Lynch Pharmaceutical HOLDRs Trust

Trump quiere que las farmacéuticas vuelvan a EE. UU. ¿Cómo afectarán sus aranceles a las acciones del sector?

Trump presiona a farmacéuticas con aranceles para forzar regreso a EE. UU.

Regeneron Pharmaceuticals, Inc. - Common Stock

Regeneron Pharmaceuticals Inc

Regnum Corp

On Tuesday, Regeneron Pharmaceuticals&nbsp;Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) &nbsp;reported first-quarter adjusted earnings per share of $8.22, down 14% year-over-year, missing the&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus of $8.82</a>.
The <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/g45061738/regeneron-reports-first-quarter-2025-financial-and-operating-results" rel="noreferrer noopener">company reported sales</a> of $3.03 billion, down 4%, missing the&nbsp;consensus of $3.29 billion.
In the first quarter, U.S. net sales for Eylea HD&nbsp;and Eylea&nbsp;decreased 26% year-over-year to $1.04&nbsp;billion, including $307 million from Eylea HD.
Also Read:&nbsp;<a target="_blank" href="https://www.benzinga.com/25/04/44870253/fda-accepts-priority-review-of-regenerons-flagship-drug-eylea-hd-for-expanded-use" rel="noreferrer noopener">FDA Sets The Countdown: Regeneron&#8217;s Eylea HD Could Be Headed For Major Expansion</a>
Net product sales of Eylea HD increased in the first quarter of 2025, compared to the first quarter of 2024, primarily due to higher sales volumes.
Net product sales of Eylea in the first quarter of 2025, compared to the first quarter of 2024, were negatively impacted by
<ul>
<li>Lower volume due to continued competitive pressures, loss in market share to compounded bevacizumab due to patient affordability constraints, and the continued transition of patients to Eylea HD</li>
<li>Lower net selling price.</li>
</ul>
Regeneron said Eylea&#8217;s net product sales have been, and are likely to continue to be, negatively impacted by increased competition from other anti-VEGF products, including biosimilars, and the transition of patients from Eylea to Eylea HD.
Sanofi collaboration revenue increased in the first quarter of 2025, compared to the first quarter of 2024, due to an increase in the company&#8217;s share of profits from the commercialization of antibodies, which were $1.018 billion and $804&nbsp;million in the first quarter of 2025 and 2024, respectively.
The change in the company&#8217;s share of profits from the commercialization of antibodies was driven by higher profits associated with an increase in Dupixent sales.
Last Tuesday, Regeneron announced a significant expansion of its manufacturing capacity through a new agreement with FUJIFILM Diosynth Biotechnologies to manufacture and supply bulk drug products of Regeneron&#8217;s commercial biologic medicines at their Holly Springs,&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/25/04/44931246/regeneron-partners-with-japan-based-fujifilm-to-bolster-us-manufacturing-capacity-via-3-billion-deal" rel="noreferrer noopener">North Carolina, campus</a>.
Guidance: Regeneron now expects a 2025 GAAP gross margin of 83%–84%, down from prior guidance of 84%–85%. The company expects an adjusted gross margin of 86%–87%, compared to the <a target="_blank" href="https://www.benzinga.com/25/02/43470883/regenerons-q4-earnings-surpass-estimates-launches-quarterly-dividend-and-additional-stock-buyback-program" rel="noreferrer noopener">prior guidance of 87%–88%</a>.
On Monday, the European Commission granted conditional marketing approval to Regeneron&#8217;s Lynozyfic (linvoseltamab) to treat adults with relapsed and <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/g45035049/lynozyfic-linvoseltamab-approved-in-the-european-union-for-the-treatment-of-relapsedrefractory-mul" rel="noreferrer noopener">refractory multiple myeloma</a>.
In the&nbsp;U.S., the&nbsp;FDA accepted for review the Biologics License Application for linvoseltamab in adults with R/R MM with a target action date of July 10, 2025.
Price Action: REGN stock is down 6.38% to $571.90 at the last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/25/04/45073128/pfizers-covid-windfall-shrinks-expands-cost-cutting-efforts" target="_blank" rel="noreferrer noopener">Pfizer&#8217;s Covid Windfall Shrinks, Expands Cost-Cutting Efforts</a></li>
</ul>
Photo by Marianne Campolongo via Shutterstock

Biotech

Earnings

Large Cap

Guidance

Health Care

Movers

Trading Ideas

General

Regeneron Pharma Margins Tighten As Competition Grows, Stock Slides

Wall Street rose modestly by midday Tuesday, as investors weighed the latest developments in trade negotiations and awaited a wave of key economic data and corporate earnings set for <a href="https://www.benzinga.com/25/04/45072497/us-trade-deficit-explodes-to-record-162-billion-in-march-as-import-frenzy-precedes-trumps-tariff-barrage">release later this week.</a>
President Donald Trump is <a href="https://apnews.com/article/trump-tariffs-automakers-factories-relief-25a400c98e02c01c8c54502384e267e1">expected</a> to unveil a new executive order on auto tariffs later today. Meanwhile, U.S. Treasury Secretary Bessent added that the administration is pursuing bilateral trade agreements with 17 major partners, excluding China.
The S&amp;P 500 climbed 0.4%, putting it on track for a sixth consecutive gain—its longest winning streak since November 2024.
In the bond market, U.S. Treasuries extended their rally, with yields falling for a sixth straight session. The yield on the 10-year benchmark dropped to 4.17%, marking a two-week low.
Gold prices slipped 0.6% to $3,325 per ounce, while WTI crude oil futures fell 2.4% to $60 per barrel, the lowest level in two weeks. Oil prices are under pressure from escalating global trade tensions and weaker U.S. economic data, and crude is now on track for a 15% decline in April—its steepest monthly drop since 2021.
Bitcoin traded little changed, around $95,000.
<h3 class="wp-block-heading">Tuesday&#8217;s Performance In Major US Indices, ETFs</h3>
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Major Indices</td>
<td>Price</td>
<td>Chg</td>
<td>1-day %</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>40,513.32</td>
<td>+285.73</td>
<td>0.7%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>5,548.89</td>
<td>+20.14</td>
<td>0.4%</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>19,468.38</td>
<td>+41.09</td>
<td>0.2%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>1,969.38</td>
<td>+3.83</td>
<td>0.2%</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Updated by 12:40 p.m. ET</figcaption></figure>
According to&nbsp;<a href="https://www.benzinga.com/pro/?utm_source=BZprocontent&amp;t=be2bearmibe3na1">Benzinga Pro</a>&nbsp;data:
<ul>
<li>The&nbsp;SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) inched 0.4% up to $552.91.</li>
<li>The&nbsp;SPDR Dow Jones Industrial Average&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>) rose 0.7% to $404.9.</li>
<li>The tech-heavy&nbsp;Invesco QQQ Trust Series&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>)&nbsp;edged 0.3% higher to $473.78.</li>
<li>The&nbsp;iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) rose 0.5% to $195.96.</li>
<li>The&nbsp;Materials&nbsp;Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLB#NYSE">XLB</a>) outperformed, up 0.8%; the&nbsp;Energy&nbsp;Select Sector SPDR Fund&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLE#NYSE">XLE</a>) lagged, down 0.5%.</li>
</ul>
<h3 class="wp-block-heading">Tuesday&#8217;s Stock Movers</h3>
Stocks moving on earnings report included:
<ul>
<li>Waste Management, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WM#NYSE">WM</a>): down 0.6%</li>
<li>Cadence Design Systems, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDNS#NASDAQ">CDNS</a>): up 4.0%</li>
<li>Brown &amp; Brown, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRO#NYSE">BRO</a>): down 6.3%</li>
<li>Nucor Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NUE#NYSE">NUE</a>): up 0.9%</li>
<li>F5 Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FFIV#NASDAQ">FFIV</a>): down 0.9%</li>
<li>Alexandria Real Estate Equities Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARE#NYSE">ARE</a>): down 6.7%</li>
<li>Teradyne, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TER#NASDAQ">TER</a>): down 1.0%</li>
<li>S&amp;P Global Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPGI#NYSE">SPGI</a>): up 2.7%</li>
<li>Honeywell International Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HON#NASDAQ">HON</a>): up 5.0%</li>
<li>American Tower Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMT#NYSE">AMT</a>): up 4.3%</li>
<li>Sherwin-Williams Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHW#NYSE">SHW</a>): up 5.2%</li>
<li>Regeneron Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>): down 7.7%</li>
<li>Zebra Technologies Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZBRA#NASDAQ">ZBRA</a>): up 6.1%</li>
<li>Ecolab, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ECL#NYSE">ECL</a>): up 2.2%</li>
<li>Hilton Worldwide Holdings Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HLT#NYSE">HLT</a>): up 1.6%</li>
<li>Labcorp Holdings Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LH#NYSE">LH</a>): up 2.3%</li>
<li>Royal Caribbean Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RCL#NYSE">RCL</a>): down 1.6%</li>
<li>United Parcel Service, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UPS#NYSE">UPS</a>): down 0.5%</li>
<li>General Motors Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GM#NYSE">GM</a>): down 0.7%</li>
<li>PayPal Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PYPL#NASDAQ">PYPL</a>): up 1.9%</li>
<li>Pfizer Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>): up 4.4%</li>
<li>Coca-Cola Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KO#NYSE">KO</a>): up 0.8%</li>
<li>Sysco Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYY#NYSE">SYY</a>): up 0.4%</li>
<li>Xylem Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XYL#NYSE">XYL</a>): up 1.5%</li>
<li>Incyte Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INCY#NASDAQ">INCY</a>): up 1.5%</li>
<li>Altria Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MO#NYSE">MO</a>): up 0.7%</li>
<li>Corning, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GLW#NYSE">GLW</a>): up 2.5%</li>
<li>Paccar Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCAR#NASDAQ">PCAR</a>): down 3.0%</li>
<li>A.O. Smith Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AOS#NYSE">AOS</a>): up 4.0%</li>
<li>Kraft Heinz Co. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KHC#NASDAQ">KHC</a>): up 0.5%</li>
<li>Entergy Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ETR#NYSE">ETR</a>): down 1.4%</li>
</ul>
Stocks slated to report earnings after the bell include Arch Capital Group Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACGL#NASDAQ">ACGL</a>), Booking Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BKNG#NASDAQ">BKNG</a>), Mondelez International, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDLZ#NASDAQ">MDLZ</a>), Caesars Entertainment, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CZR#NASDAQ">CZR</a>), Veralto Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VLTO#NYSE">VLTO</a>), Seagate Technology Holdings PLC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STX#NASDAQ">STX</a>), Starbucks Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBUX#NASDAQ">SBUX</a>), Extendicare Inc. (TSE: EXE), Fair Isaac Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FICO#NYSE">FICO</a>), Visa Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/V#NYSE">V</a>), Boston Properties, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BXP#NYSE">BXP</a>), PPG Industries, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PPG#NYSE">PPG</a>), Extra Space Storage Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EXR#NYSE">EXR</a>), Edison International (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EIX#NYSE">EIX</a>), ONEOK, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OKE#NYSE">OKE</a>), First Solar, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FSLR#NASDAQ">FSLR</a>), CoStar Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSGP#NASDAQ">CSGP</a>), Regency Centers Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REG#NASDAQ">REG</a>), Essex Property Trust, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ESS#NYSE">ESS</a>), and Equity Residential (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EQR#NYSE">EQR</a>).
Now Read: 
<ul>
<li><a href="https://www.benzinga.com/25/04/45074861/us-consumer-expectations-falls-to-13-year-lows-as-recession-fears-inflation-worries-surge">US Consumer Expectations Falls To 13-Year Lows As Recession Fears, Inflation Worries Surge</a></li>
</ul>
Image: Shutterstock

Macro Economic Events

Broad U.S. Equity ETFs

Economics

ETFs

ACGL

BKNG

CDNS

CSGP

SPDR Dow Jones Industrial Average ETF Trust

FFIV

FICO

FSLR

INCY

Laboratory Corporation Of America Holdings

MDLZ

PCAR

PYPL

SBUX

SPGI

VLTO

Select Sector SPDR-Consumer Discretionary

ZBRA

Stocks Surge And Bond Yields Fall For 6th Day, Oil Prices Drop To $60: What's Driving Markets Tuesday?

U.S. stock futures were higher this morning, with the Dow futures gaining around 100 points on Tuesday.
Shares of NXP Semiconductors N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXPI#NASDAQ">NXPI</a>) fell sharply in today's pre-market trading after the company reported first-quarter financial results and issued second-quarter EPS guidance with its <a href="https://in.benzinga.com/news/management/25/04/45053723/nxp-semiconductors-reports-q1-earnings-very-uncertain-operating-environment-tied-to-tariffs-ceo-transition-shares-fall">midpoint below estimates</a>.
NXP reported first-quarter revenue of $2.84 billion, in line with analyst estimates, according to Benzinga Pro. The company reported first-quarter adjusted earnings of $2.64 per share, beating analyst estimates of $2.58 per share.
NXP expects second-quarter revenue of $2.8 billion to $3 billion versus estimates of $2.87 billion. The company sees second-quarter adjusted earnings in the range of $2.46 to $2.86 per share versus estimates of $2.65 per share. The company announced CEO Kurt Sievers will retire at the end of 2025.
NXP Semiconductors shares dipped 7.7% to $181.18 in the pre-market trading session.
Here are some other stocks moving lower in pre-market trading.
<ul>
<li>Ultra Clean Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UCTT#NASDAQ">UCTT</a>) fell 10.3% to $20.00 in pre-market trading after the company reported worse-than-expected first-quarter financial result and issued second-quarter guidance below estimates.</li>
<li>Hope Bancorp, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOPE#NASDAQ">HOPE</a>) declined 9.5% to $9.02 in pre-market trading.</li>
<li>Brinker International, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EAT#NYSE">EAT</a>) dipped 8.6% to $146.90 in pre-market trading following third-quarter results.</li>
<li>Spotify Technology S.A. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPOT#NYSE">SPOT</a>) fell 8.5% to $547.00 in pre-market trading after the company reported worse-than-expected quarterly earnings.</li>
<li>Syndax Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNDX#NASDAQ">SNDX</a>) fell 7.5% to $12.42 in pre-market trading. Syndax Pharmaceuticals will report its first quarter financial results and provide a business update on Monday, May 5.</li>
<li>Regeneron Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) fell 7% to $568.00 in pre-market trading following weak quarterly earnings.</li>
<li>Sanmina Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SANM#NASDAQ">SANM</a>) fell 5.8% to $76.00 in today's pre-market trading. Sanmina posted upbeat results for its second quarter, but issued weak forecast for the third quarter. The company said it sees third-quarter adjusted earnings of $1.35 to $1.45 per share, versus market estimates of $1.53 per share. It also expects sales of $1.925 billion to $2.025 billion for the current quarter, versus market projections of $2.06 billion.</li>
<li>XPeng Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPEV#NYSE">XPEV</a>) fell 4.7% to $18.99 in pre-market trading.</li>
<li>BP p.l.c. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BP#NYSE">BP</a>) declined 4.3% to $27.87 in pre-market trading following first-quarter earnings.</li>
<li>AstraZeneca PLC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>) fell 2.8% to $67.96 in pre-market trading following quarterly results.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/25/04/45060164/general-motors-coca-cola-and-3-stocks-to-watch-heading-into-tuesday">General Motors, Coca-Cola And 3 Stocks To Watch Heading Into Tuesday</a> </li>
</ul>
Photo via Shutterstock

Pre-Market Outlook

HOPE

NXPI

SANM

SNDX

SPOT

UCTT

XPEV

NXP Semiconductors, Brinker International, Ultra Clean, Sanmina And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

WIIM

Regeneron Pharmaceuticals shares are trading lower after the company reported wore-than-expected Q1 financial results.

Regeneron Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) reported quarterly earnings of $8.22 per share which missed the analyst consensus estimate of $8.82 by 6.8 percent. This is a 13.93 percent decrease over earnings of $9.55 per share from the same period last year. The company reported quarterly sales of $3.03 billion which missed the analyst consensus estimate of $3.29 billion by 7.97 percent. This is a 3.69 percent decrease over sales of $3.15 billion the same period last year.

Earnings Misses

Regeneron Pharmaceuticals Q1 Adj. EPS $8.22 Misses $8.82 Estimate, Sales $3.03B Miss $3.29B Estimate

AEYE

AMSF

APAM

ARCB

ARCC

ASTE

ASTL

ATRC

BBIO

BBVA

BGFV

BRSP

CECO

CHCT

CLVT

CVLT

DHIL

ENSG

ENVA

ESRT

ETWO

EXLS

FELE

FFIC

FIBK

FOUR

FRSH

FRST

FYBR

HLMN

HOUS

HRZN

HSBC

HURN

ILPT

INTZ

JAKK

JBGS

JBLU

KNSA

LFUS

LGIH

LOGI

LXFR

Earnings Scheduled For April 29, 2025

Regeneron Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) will release its quarterly earnings report on Tuesday, 2025-04-29. Here's a brief overview for investors ahead of the announcement.
Analysts anticipate Regeneron Pharmaceuticals to report an earnings per share (EPS) of $9.22.
Anticipation surrounds Regeneron Pharmaceuticals's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.
New investors should understand that while earnings performance is important, market reactions are often driven by guidance.
<h3>Earnings Track Record</h3>
The company's EPS beat by $0.88 in the last quarter, leading to a 2.82% increase in the share price on the following day.
Here's a look at Regeneron Pharmaceuticals's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>11.19</td>
<td>11.69</td>
<td>10.53</td>
<td>10.10</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>12.07</td>
<td>12.46</td>
<td>11.56</td>
<td>9.55</td>
</tr>
<tr>
<td>Price Change %</td>
<td>3.0%</td>
<td>1.0%</td>
<td>-1.0%</td>
<td>2.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1745848875_0.png" alt="eps graph" />
<h3>Performance of Regeneron Pharmaceuticals Shares</h3>
Shares of Regeneron Pharmaceuticals were trading at $602.64 as of April 25. Over the last 52-week period, shares are down 31.6%. Given that these returns are generally negative, long-term shareholders are likely unhappy going into this earnings release. 
<h3>Analyst Observations about Regeneron Pharmaceuticals</h3>
For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on Regeneron Pharmaceuticals.
Regeneron Pharmaceuticals has received a total of 10 ratings from analysts, with the consensus rating as Buy. With an average one-year price target of $797.9, the consensus suggests a potential 32.4% upside.
<h3>Understanding Analyst Ratings Among Peers</h3>
This comparison focuses on the analyst ratings and average 1-year price targets of argenx and Alnylam Pharmaceuticals, three major players in the industry, shedding light on their relative performance expectations and market positioning.
<ul>
<li>Analysts currently favor an Buy trajectory for argenx, with an average 1-year price target of $755.64, suggesting a potential 25.39% upside.</li>
<li>Analysts currently favor an Buy trajectory for Alnylam Pharmaceuticals, with an average 1-year price target of $342.15, suggesting a potential 43.22% downside.</li>
</ul>
<h3>Analysis Summary for Peers</h3>
The peer analysis summary presents essential metrics for argenx and Alnylam Pharmaceuticals, unveiling their respective standings within the industry and providing valuable insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Regeneron Pharmaceuticals</td>
<td>Buy</td>
<td>10.33%</td>
<td>$3.22B</td>
<td>3.13%</td>
</tr>
<tr>
<td>argenx</td>
<td>Buy</td>
<td>81.50%</td>
<td>$665.75M</td>
<td>14.08%</td>
</tr>
<tr>
<td>Alnylam Pharmaceuticals</td>
<td>Buy</td>
<td>34.90%</td>
<td>$490.35M</td>
<td>-168.47%</td>
</tr>
</tbody>
</table>

Key Takeaway:
Regeneron Pharmaceuticals ranks highest in Gross Profit among its peers. It is in the middle for Revenue Growth and Return on Equity.
<h3>All You Need to Know About Regeneron Pharmaceuticals</h3>
Regeneron Pharmaceuticals Inc discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).
<h3>Financial Milestones: Regeneron Pharmaceuticals's Journey</h3>
Market Capitalization: Exceeding industry standards, the company's market capitalization places it above industry average in size relative to peers. This emphasizes its significant scale and robust market position.
Revenue Growth: Over the 3 months period, Regeneron Pharmaceuticals showcased positive performance, achieving a revenue growth rate of 10.33% as of 31 December, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of 24.22%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): Regeneron Pharmaceuticals's ROE excels beyond industry benchmarks, reaching 3.13%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 2.44%, the company showcases effective utilization of assets.
Debt Management: Regeneron Pharmaceuticals's debt-to-equity ratio is below the industry average. With a ratio of 0.09, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<a href="https://www.benzinga.com/quote/REGN/earnings">To track all earnings releases for Regeneron Pharmaceuticals visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insights into Regeneron Pharmaceuticals's Upcoming Earnings

Initial real-world data from nearly 40,000 EYLEA HD patients will provide early insights on effectiveness of EYLEA HD in everyday clinical practice
New indirect comparisons will evaluate EYLEA HD and faricimab on measures of efficacy, dosing frequency and potential economic benefits in patients with wet age-related macular degeneration and diabetic macular edema
&nbsp;Regeneron Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) today announced the upcoming presentation of 27 abstracts, including eight oral presentations on EYLEA HD&#xAE; (aflibercept) Injection 8 mg in wet age-related macular degeneration (wAMD), diabetic macular edema (DME) and diabetic retinopathy (DR). Among the new results and analyses are initial insights on the real-world use of EYLEA HD in clinical practice, which reinforce the outcomes seen in pivotal trials. These data will be presented at the Association for Research in Vision and Ophthalmology (ARVO) 2025 Annual Meeting from May 4 to 8 in Salt Lake City.
"Our data presentations at ARVO reflect the robust and rapidly growing body of evidence that support the use of EYLEA HD becoming the new standard of care for people living with wet age-related macular degeneration, diabetic macular edema and diabetic retinopathy," said Boaz Hirshberg, M.D., Senior Vice President, Clinical Development, Internal Medicine at Regeneron. "This includes new analyses examining the initial real-world experiences of nearly 40,000 patients treated with EYLEA HD showing, in everyday clinical practice, a positive impact through improved vision and longer dosing intervals for patients. Although early, these data reinforce the value EYLEA HD is bringing to patients with serious retinal diseases."
Notable new presentations at ARVO include:
<ul>
<li>Four analyses evaluating initial real-world experiences with EYLEA HD among patients with wAMD or DME, including both those who were previously naive to treatment and those who switched from other anti-vascular endothelial growth factor (VEGF) therapies</li>
<li>A network meta-analysis indirectly comparing the efficacy and number of injections received for EYLEA HD and faricimab in patients with DME or wAMD, based on the longest follow-up data from Phase 3 clinical trials</li>
<li>A modeling analysis of the potential economic benefit of EYLEA HD compared to faricimab for the treatment of patients with wAMD or DME in the U.S. over three years &nbsp;</li>
</ul>
The most common adverse reactions (≥3%) reported in patients treated with EYLEA&nbsp;HD were cataract, conjunctival hemorrhage, intraocular pressure increased, ocular discomfort/eye pain/eye irritation, vision blurred, vitreous floaters,&nbsp;vitreous detachment, corneal epithelium defect and retinal hemorrhage.&nbsp;

Regeneron Pharmaceuticals Announces The Upcoming Presentation Of 27 Abstracts, Including Eight Oral Presentations On EYLEA HD Injection 8 MG . Data Will Be Presented at the Association For Research In Vision and Ophthalmology 2025 Annual Meeting May 4 To 8 in Salt Lake City, Utah

Approval of Lynozyfic is based on data showing deep and durable responses in relapsed/refractory multiple myeloma
Lynozyfic will provide a new option with&nbsp;convenient dosing and administration to patients who face cycles of relapse and remission
&nbsp;Regeneron Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) today announced that the European Commission (EC) has granted conditional marketing approval of Lynozyfic&#x2122; (linvoseltamab) to treat adults with relapsed and refractory (R/R) multiple myeloma (MM). The indication is specific to those who have received at least three prior therapies, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy. Lynozyfic is a bispecific antibody designed to bridge B-cell maturation antigen (BCMA) on MM cells with CD3-expressing T cells to facilitate T-cell activation and cancer-cell killing.
Lynozyfic is the first BCMAxCD3 therapy approved that can be dosed every four weeks due to a response-adapted regimen if a very good partial response (VGPR) or better is achieved following completion of at least 24 weeks of therapy. The regimen includes monitoring in close proximity of a qualified treatment center for safety during the step-up dosing period (one 24-hour period after the first step-up dose and another 24-hour period after the second step-up dose, if certain safety events occur).
"Despite treatment advances, patients with multiple myeloma inevitably endure relapses, reduced responses to subsequent therapies, and increasingly shorter remissions. For those who develop relapsed and refractory disease after having been exposed to the three major drug classes, it's important to have new therapies with different mechanisms of action like linvoseltamab," said Paula Rodriguez-Otero, M.D., Department of Hematology, Cancer Center Clínica Universidad de Navarra, Pamplona, Navarra, Spain. "In a clinical trial, linvoseltamab demonstrated compelling and impressive efficacy with the potential for complete remission in this patient population, including those with high disease burden. Furthermore, its response-adapted schedule will provide patients a convenient treatment option."
The EC approval is based on results from the pivotal LINKER-MM1 trial (n=117 at the 200 mg dose of Lynozyfic), which demonstrated robust and durable responses in patients with R/R MM. Results showed a 71% objective response rate (ORR), with 50% of patients achieving a complete response (CR) or better, as determined by an independent review committee. The minimal residual disease (MRD) negativity rate in patients achieving a CR or stringent CR was 41% (24 of 58 patients; 95% confidence interval [CI]: 29 to 55). The median duration of response (DOR) was 29 months (95% CI: 19 to not estimable).
The most frequent adverse reactions were musculoskeletal pain (52%), cytokine release syndrome (CRS; 46%), neutropenia (43%), cough (42%), diarrhea&nbsp;(39%), anemia (38%), fatigue (36%), pneumonia (32%), and upper respiratory tract infection (30%).&nbsp;The majority of CRS cases were Grade 1 (35%) or Grade 2 (10%), and there was one case of Grade 3 CRS (0.9%) and no cases of ≥Grade 4 CRS. The median time to first CRS onset was 11 hours (range: -1.1 to 184 hours), with the median time to resolution within 1 day (16 hours; range: 1-96 hours). Grade 3 immune effector cell-associated neurotoxicity syndrome (ICANS; 2.6%) and infections that were Grade 3 or 4 (36%) or fatal (4%) also occurred.
"Lynozyfic is our second approved bispecific antibody – in this case for relapsed/refractory multiple myeloma patients – reinforcing our relentless commitment to transforming cancer care for those who need it most," said George D. Yancopoulos, M.D., Ph.D., Board co-Chair, President and Chief Scientific Officer of Regeneron. "We are excited by the potential of Lynozyfic and its differentiated clinical profile, dosing and administration. Given the strength of the data, we are pursuing a robust clinical development program exploring its use – in earlier lines of therapy as monotherapy and in novel combinations – with the hope of further advancing care for patients."

Regeneron Pharmaceuticals Announces That The European Commission  Has Granted Conditional Marketing Approval Of Lynozyfic To Treat Adults With Relapsed And Refractory Multiple Myeloma

Baird analyst Brian Skorney maintains Regeneron Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) with a Neutral and lowers the price target from $759 to $652.

Price Target

Analyst Ratings

Baird Maintains Neutral on Regeneron Pharmaceuticals, Lowers Price Target to $652

Truist Securities analyst Srikripa Devarakonda maintains Regeneron Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) with a Buy and lowers the price target from $1004 to $975.

Truist Securities Maintains Buy on Regeneron Pharmaceuticals, Lowers Price Target to $975

Regeneron Pharmaceuticals, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) on Tuesday announced a significant expansion of its manufacturing capacity through a new agreement with FUJIFILM Diosynth Biotechnologies to manufacture and supply bulk drug products of Regeneron&#8217;s commercial biologic medicines at their Holly Springs, <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">North Carolina, campus</a>.
Regeneron, already one of the world&#8217;s largest biologics manufacturers, will nearly double its U.S. large-scale manufacturing capacity by accessing Fujifilm&#8217;s <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/g44916999/regeneron-announces-new-investment-in-manufacturing-of-its-industry-leading-biologic-medicines" rel="noreferrer noopener">new biopharmaceutical facility</a>.
With technology transfer beginning immediately and a 10-year term, the total investment is estimated to exceed $3 billion.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/04/44870253/fda-accepts-priority-review-of-regenerons-flagship-drug-eylea-hd-for-expanded-use" rel="noreferrer noopener">FDA Sets The Countdown: Regeneron&#8217;s Eylea HD Could Be Headed For Major Expansion</a>
&#8220;Regeneron is an American success story, with over 80 percent of our workforce and assets in the U.S. and all of our FDA-approved medicines invented in our New York laboratories&#8230;&#8221; said Leonard Schleifer, Board co-Chair, president and CEO of Regeneron.
&#8220;FUJIFILM Diosynth Biotechnologies will be bringing additional capacity online in 2025, 2026 and beyond as it completes the current $7 billion of expansion projects underway in both Europe and United States,&#8221; &nbsp;said Toshihisa Iida, director, corporate vice president, general manager of Life Sciences Strategy Headquarters and Bio-CDMO Division,<a href="https://www.benzinga.com/pressreleases/25/04/b44917015/fujifilm-diosynth-biotechnologies-and-regeneron-sign-a-10-year-u-s-manufacturing-agreement-valued-" target="_blank" rel="noreferrer noopener"> FUJIFILM Corporation, Japan</a>.
Regeneron continues to invest heavily in its New York State operations. An approximately $3.6 billion expansion of its Tarrytown campus is underway, creating 1,000 full-time, high-skill jobs and expanding research, preclinical manufacturing, and support facilities.
In addition, the company is constructing a brand new fill/finish manufacturing facility in Rensselaer, New York. It has acquired an over 1 million-square-foot property in Saratoga Springs, New York, for production support activities and, potentially, additional manufacturing capacity.
Regeneron has added more than 7,000 jobs in the past five years, most of which are high-paying R&amp;D and manufacturing jobs based in the U.S.
Regeneron&#8217;s ongoing and planned investments in New York and North Carolina infrastructure and manufacturing are expected to total more than $7 billion.
On Friday, the U.S. Food and Drug Administration (FDA) issued a complete response letter (CRL) regarding the supplemental Biologics License Application (sBLA) for the addition of extended dosing intervals (up to every 24 weeks) for Regeneron&#8217;s Eylea (aflibercept) Injection 8 mg <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/g44886470/regeneron-provides-update-on-eylea-hd-aflibercept-injection-8-mg-supplemental-biologics-license-ap" rel="noreferrer noopener">across all approved indications</a>.
The CRL did not identify any issues with the safety or efficacy of Eylea HD in its approved indications and dosing regimens. The FDA did not agree with Regeneron&#8217;s proposal to add additional extended dosing intervals (greater than every 16 weeks, which is the maximum dosing interval currently indicated in the label). Regeneron is evaluating the FDA&#8217;s decision.
On Friday, the FDA approved Regeneron and Sanofi SA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>) partnered Dupixent&nbsp;(dupilumab) for adults and adolescents aged 12 years and older with chronic spontaneous urticaria (CSU) who remain symptomatic despite histamine-1 (H1) <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/g44884755/dupixent-dupilumab-approved-in-the-u-s-as-the-first-new-targeted-therapy-in-over-a-decade-for-chro" rel="noreferrer noopener">antihistamine treatment</a>.
Price Action: REGN stock is up 4.2% at $585.25 at last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/04/44922218/lockheed-martin-posts-strong-q1-says-maintained-2025-guidance-doesnt-include-tariff-impact" target="_blank" rel="noreferrer noopener">Lockheed Martin Does Not Alter Annual Outlook To Price Tariff Impact Yet Amid Recent CFO Change</a></li>
</ul>
Photo: Shutterstock

Regeneron Expands US Manufacturing With $3 Billion Fujifilm Deal

Canaccord Genuity analyst John Newman maintains Regeneron Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) with a Buy and lowers the price target from $1152 to $850.

Canaccord Genuity Maintains Buy on Regeneron Pharmaceuticals, Lowers Price Target to $850

Cantor Fitzgerald analyst Carter Gould assumes Regeneron Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) with a Overweight rating and announces Price Target of $695.

Initiation

Cantor Fitzgerald Assumes Regeneron Pharmaceuticals at Overweight, Announces Price Target of $695

FUJIFILM Diosynth Biotechnologies Ink 10-Year Manufacturing Supply Agreement Worth $3B With Regeneron Pharmaceuticals

Reported Friday, Regeneron Receives FDA Complete Response On EYLEA HD Application, No Safety Or Efficacy Issues Identified

Regeneron Pharmaceuticals And Sanofi Announce FDA Approval of Dupixent For Chronic Spontaneous Urticaria in Adults and Adolescents

The U.S. Food and Drug Administration has accepted for Priority Review Regeneron Pharmaceuticals, Inc.&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) supplemental Biologics License Application (sBLA) for Eylea HD <a href="https://www.benzinga.com/general/health-care" target="_blank" rel="noreferrer noopener">(aflibercept) Injection 8 mg</a>.
The sBLA seeks approval for Eylea HD for macular edema following retinal vein occlusion (RVO) and broadening the dosing schedule to include every 4-week (monthly) dosing <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/g44859817/eylea-hd-aflibercept-injection-8-mg-sbla-accepted-for-fda-priority-review-for-both-the-treatment-o" rel="noreferrer noopener">across approved indications</a>.
The FDA target action date is&nbsp;August 19, 2025,&nbsp;following the use of a Priority Review voucher.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/04/44652995/vertex-alnylam-best-positioned-as-biopharma-braces-for-tariff-impact-goldman-sachs-analyst-flags-regeneron-biogen-risks" rel="noreferrer noopener">Vertex, Alnylam Best Positioned As Biopharma Braces For Tariff Impact, Goldman Sachs Flags Regeneron, Biogen Risks</a>
Data from the Eylea HD clinical program, including the Phase 3 QUASAR trial investigating Eylea HD in RVO, support the sBLA.
As previously&nbsp;<a target="_blank" href="https://www.globenewswire.com/Tracker?data=lIY80eDymaJZTWtLLbkBCRJgLnw2xcuCCdcj05NnO7aQugCej2rSB-zxhlnSmVvIJtcp9WlMpwFT7g_ixbuUN_6RxF6YOpU3cekCfcfehEuYFoUswmcHNzGl7qhrlOJZcZAltDicvv2wm386xTGOL0rcZwEQtPkSCfofA-sVLXVcoWFLTd20X7qrroJsJlKLtw6Q0ijcy5JR997n5OTAAbcjYhY8cPLAy5AzmGBZOHU=&amp;tblci=GiCUX7wvU_AgmIIiQduNYr6JQuJQLy6SZJGvpyeZuCzyqiCN1VcoxvTN4f7-y-PqATDviEo" rel="noreferrer noopener">presented</a>, QUASAR met its primary endpoint at 36 weeks. Eylea HD patients were dosed every 8 weeks (after 3 or 5 monthly doses), achieving non-inferior visual acuity gains compared to those receiving Eylea&nbsp;(aflibercept) Injection 2 mg dosed every 4 weeks.
All anti-VEGF therapies approved to treat RVO, including Eylea, are indicated for monthly dosing.
In QUASAR, the safety profile of EYLEA HD (n=591) was similar to Eylea (n=301). It remained generally consistent with the known safety profile of Eylea HD in its pivotal trials for approved indications and with the <a target="_blank" href="https://www.benzinga.com/24/12/42536756/regenerons-best-selling-eye-drug-eyleas-higher-dose-formulation-meets-primary-goal-in-another-form-of-retinal-disease-study" rel="noreferrer noopener">established safety profile of Eylea</a>.
Increased ocular pressure (5%) was the only ocular treatment-emergent adverse event that occurred in ≥5% of all Eylea HD patients, compared to 1.7% of Eylea patients.
There was one case each of endophthalmitis and retinal vasculitis in all Eylea HD patients, compared to two cases of endophthalmitis and no cases of retinal vasculitis in Eylea patients.
No cases of occlusive retinal vasculitis were reported. The rate of intraocular inflammation was 0.5% for Eylea HD and 1.3% for Eylea.
The safety and efficacy of Eylea HD for RVO and monthly dosing in approved indications have not been evaluated by any regulatory authority.
B of A Securities maintains Regeneron Pharmaceuticals with an Underperform and lowers the price <a target="_blank" href="https://www.benzinga.com/quote/REGN/analyst-ratings" rel="noreferrer noopener">target from $575 to $547</a>.
Price Action: REGN stock is up 1.3% at $556.48 at the last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/dividends/25/04/44863342/retail-giant-costco-raises-dividend-by-12" target="_blank" rel="noreferrer noopener">Retail Giant Costco Raises Dividend By 12%</a></li>
</ul>
Photo: Gorodenkoff/Shutterstock

FDA Sets The Countdown: Regeneron's Eylea HD Could Be Headed For Major Expansion

Providing a diverse range of perspectives from bullish to bearish, 7 analysts have published ratings on Regeneron Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) in the last three months.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $831.43, with a high estimate of $1013.00 and a low estimate of $547.00. Highlighting a 8.86% decrease, the current average has fallen from the previous average price target of $912.29. 
<img src="https://www.benzinga.com/files/images/story/2025/1744891323_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
A comprehensive examination of how financial experts perceive Regeneron Pharmaceuticals is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Tim Anderson &#x7C;B of A Securities &#x7C;Lowers &#x7C;Underperform &#x7C; $547.00&#x7C;$575.00 &#x7C; 
&#x7C;Salveen Richter &#x7C;Goldman Sachs &#x7C;Lowers &#x7C;Buy &#x7C; $917.00&#x7C;$1019.00 &#x7C; 
&#x7C;Chris Schott &#x7C;JP Morgan &#x7C;Lowers &#x7C;Overweight &#x7C; $1000.00&#x7C;$1100.00 &#x7C; 
&#x7C;Brian Skorney &#x7C;Baird &#x7C;Lowers &#x7C;Neutral &#x7C; $759.00&#x7C;$940.00 &#x7C; 
&#x7C;David Risinger &#x7C;Leerink Partners &#x7C;Raises &#x7C;Outperform &#x7C; $834.00&#x7C;$762.00 &#x7C; 
&#x7C;Geoff Meacham &#x7C;Citigroup &#x7C;Lowers &#x7C;Neutral &#x7C; $750.00&#x7C;$795.00 &#x7C; 
&#x7C;Christopher Raymond &#x7C;Piper Sandler &#x7C;Lowers &#x7C;Overweight &#x7C; $1013.00&#x7C;$1195.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Regeneron Pharmaceuticals. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Regeneron Pharmaceuticals compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Regeneron Pharmaceuticals's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/REGN/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Regeneron Pharmaceuticals analyst ratings.</a>
<h2>All You Need to Know About Regeneron Pharmaceuticals</h2>
Regeneron Pharmaceuticals Inc discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).
<h3>Regeneron Pharmaceuticals: Delving into Financials</h3>
Market Capitalization Highlights: Above the industry average, the company's market capitalization signifies a significant scale, indicating strong confidence and market prominence.
Positive Revenue Trend: Examining Regeneron Pharmaceuticals's financials over 3M reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 10.33% as of 31 December, 2024, showcasing a substantial increase in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Regeneron Pharmaceuticals's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of 24.22%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Regeneron Pharmaceuticals's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 3.13% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Regeneron Pharmaceuticals's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 2.44% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Regeneron Pharmaceuticals's debt-to-equity ratio is below the industry average. With a ratio of 0.09, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>What Are Analyst Ratings?</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Assessing Regeneron Pharmaceuticals: Insights From 7 Financial Analysts

B of A Securities analyst Tim Anderson maintains Regeneron Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) with a Underperform and lowers the price target from $575 to $547.

B of A Securities Maintains Underperform on Regeneron Pharmaceuticals, Lowers Price Target to $547

Press Releases

EYLEA HD® (aflibercept) Injection 8 mg sBLA Accepted for FDA Priority Review for Both the Treatment of Macular Edema Following Retinal Vein Occlusion (RVO) and for Monthly Dosing in Approved Indications

Press Release: Dupixent approved in the US as the first new targeted therapy in over a decade for chronic spontaneous urticaria

Dupixent® (dupilumab) Approved in the U.S. as the First New Targeted Therapy in Over a Decade for Chronic Spontaneous Urticaria (CSU)

Regeneron Provides Update on EYLEA HD® (aflibercept) Injection 8 mg Supplemental Biologics License Application

Regeneron Announces Investor Conference Presentations

Regeneron Announces New Investment in Manufacturing of its Industry-Leading Biologic Medicines

FUJIFILM Diosynth Biotechnologies and Regeneron Sign a 10-Year U.S. Manufacturing Agreement Valued at Over $3 Billion

EYLEA HD® (aflibercept) Injection 8 mg Presentations at ARVO Reinforce Continued Safety and Efficacy and Highlight Early Real-World Outcomes for Patients with Serious Retinal Disease

Lynozyfic™ (linvoseltamab) Approved in the European Union for the Treatment of Relapsed/Refractory Multiple Myeloma

Regeneron Reports First Quarter 2025 Financial and Operating Results

PARIS:SAN

AbbVie

Alnylam Pharmaceuticals, Inc. - Common Stock

Alnylam Pharmaceuticals

Amgen

argenx

Ascendis Pharma A/S - American Depositary Shares

Ascendis Pharma

Biogen

BioMarin Pharmaceutical Inc. - Common Stock

Biomarin Pharmaceutical

BioNTech

Exact Sciences Corporation - Common Stock

Exact Sciences

Exelixis

Gilead Sciences

Genmab

Halozyme Therapeutics, Inc. - Common Stock

Halozyme Therapeutics

Incyte

Insmed

Madrigal Pharmaceuticals, Inc. - Common Stock

Madrigal Pharmaceuticals

Moderna

Neurocrine Biosciences, Inc. - Common Stock

Neurocrine Biosciences

Natera

BeiGene, Ltd. - American Depositary Shares

BeiGene

Roivant Sciences

Revolution Medicines, Inc. - Common Stock

Revolution Medicines

Summit Therapeutics

United Therapeutics Corporation - Common Stock

United Therapeutics

Vertex Pharmaceuticals Incorporated - Common Stock

Vertex Pharmaceuticals

Baird

Truist Securities

Canaccord Genuity

Cantor Fitzgerald

B of A Securities

Screenshot 2024-09-10 at 8.49.39 PM

MAIA

MAIA Biotechnology&#39;s Phase 2 Study Of THIO In Non-Small Cell Lung Cancer Shows Positive Interim Survival Benefits

Comments

Regeneron Pharmaceuticals

Regeneron Pharmaceuticals (REGN) Opciones

No option chain data available. Please try again later

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL